We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA

By LabMedica International staff writers
Posted on 22 Feb 2024

Globally, an alarming one in every five deaths is attributed to complications related to sepsis, with children accounting for 41% of these fatalities. More...

Common practice involves administering antibiotics to sepsis patients while waiting for blood culture results, which can contribute to antibiotic resistance. Ineffectively treating sepsis can be detrimental, as up to 30% of patients receive incorrect treatments, further elevating their risk of death. The critical nature of timely and accurate diagnosis in sepsis cases is underscored by the fact that the mortality risk escalates by 4% every hour the infection is not properly identified or treated. Now, a new analysis technique offers quicker and more precise pathogen detection in blood samples compared to traditional blood cultures, which are the standard in infection diagnosis.

The new method, called digital DNA melting analysis, has been developed by researchers at UC San Diego (La Jolla, CA, USA) and is capable of delivering results in less than six hours. This marks a significant improvement over the typical 15 hours to several days required by culture methods, depending on the pathogen involved. The process utilizes universal digital high-resolution DNA melting, involving heating DNA until it separates. Each DNA sequence reveals a unique signature during the melting process. By imaging and analyzing this process, machine learning algorithms can discern the types of DNA in the samples and identify pathogens. This method not only outpaces blood cultures in terms of speed but also has a substantially lower risk of generating false positives compared to other emerging DNA detection technologies, such as Next Generation Sequencing.

The research began with one milliliter of blood from each of 17 patients in a preliminary clinical study. These samples were collected concurrently with those for blood cultures from infants and toddlers. The researchers honed the DNA isolation process and machine learning techniques to minimize or eliminate interference from human DNA in contrast to pathogen DNA in the samples. They refined a machine learning algorithm to accurately distinguish between the melting curves of pathogens and background noise. This algorithm correlates the observed curves with a database of known DNA melt curves. Moreover, it can identify curves produced by organisms not in this database, which is particularly useful in detecting rare or emerging pathogens in a sample.

The results from this method were not only consistent with those obtained from blood cultures of the same samples, but they also did not yield any false positives. This contrasts with other tests based on nucleic acid amplification and next-generation DNA sequencing databases, which tend to amplify all present DNA, leading to false positives. Contamination from various sources such as the environment, test tubes, reagents, and skin can often lead to challenges in interpreting test results. This new method detected pathogens 7.5 hours to approximately 3 days faster than conventional blood cultures. Additionally, it provides more than just a binary positive or negative outcome; it quantifies the extent of pathogen presence in the samples. Future plans include conducting a more extensive clinical study and extending the methodology to adult patients.

“This is the first time this method has been tested on whole blood from patients suspected of having sepsis. So this study is a more realistic preview of how the technology could perform in real clinical scenarios,” said Stephanie Fraley, a professor at the UC San Diego. “We want to give doctors the ability to treat their patients based not on aggregate data, but with precise, accurate individual data, enabling truly personalized medicine.”

Related Links:
UC San Diego


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.